1. Home
  2. BEAM vs GABC Comparison

BEAM vs GABC Comparison

Compare BEAM & GABC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BEAM
  • GABC
  • Stock Information
  • Founded
  • BEAM 2017
  • GABC 1910
  • Country
  • BEAM United States
  • GABC United States
  • Employees
  • BEAM N/A
  • GABC N/A
  • Industry
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • GABC Major Banks
  • Sector
  • BEAM Health Care
  • GABC Finance
  • Exchange
  • BEAM Nasdaq
  • GABC Nasdaq
  • Market Cap
  • BEAM 1.7B
  • GABC 1.6B
  • IPO Year
  • BEAM 2020
  • GABC N/A
  • Fundamental
  • Price
  • BEAM $21.08
  • GABC $40.76
  • Analyst Decision
  • BEAM Strong Buy
  • GABC Hold
  • Analyst Count
  • BEAM 10
  • GABC 3
  • Target Price
  • BEAM $48.56
  • GABC $45.33
  • AVG Volume (30 Days)
  • BEAM 2.9M
  • GABC 115.1K
  • Earning Date
  • BEAM 11-04-2025
  • GABC 10-27-2025
  • Dividend Yield
  • BEAM N/A
  • GABC 2.84%
  • EPS Growth
  • BEAM N/A
  • GABC N/A
  • EPS
  • BEAM N/A
  • GABC 2.62
  • Revenue
  • BEAM $60,272,000.00
  • GABC $281,091,000.00
  • Revenue This Year
  • BEAM N/A
  • GABC $45.86
  • Revenue Next Year
  • BEAM $17.95
  • GABC $6.11
  • P/E Ratio
  • BEAM N/A
  • GABC $15.62
  • Revenue Growth
  • BEAM N/A
  • GABC 13.87
  • 52 Week Low
  • BEAM $13.53
  • GABC $32.75
  • 52 Week High
  • BEAM $35.25
  • GABC $47.08
  • Technical
  • Relative Strength Index (RSI)
  • BEAM 62.10
  • GABC 51.63
  • Support Level
  • BEAM $19.57
  • GABC $40.40
  • Resistance Level
  • BEAM $21.59
  • GABC $41.13
  • Average True Range (ATR)
  • BEAM 1.24
  • GABC 0.72
  • MACD
  • BEAM 0.47
  • GABC -0.13
  • Stochastic Oscillator
  • BEAM 91.11
  • GABC 24.25

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About GABC German American Bancorp Inc.

German American Bancorp Inc is a bank holding company. The lines of business include Retail and commercial banking business which involves attracting deposits from the general public and using those funds to originate consumer, commercial and agricultural, commercial and agricultural real estate, and residential mortgage loans. These core banking activities also include the sale of residential mortgage loans in the secondary market. Wealth management services which involve providing trust, investment advisory, brokerage and retirement planning services to customers. Insurance operations include the offering of a full range of personal and corporate property and casualty insurance products.

Share on Social Networks: